BioSpace News Archive

The relationship between pharmaceutical companies and patient advocacy groups is long and deep and involves millions of dollars in donations, a new report reveals.

Pfizer joined the TriNetX global health research network, which will allow it to access clinical data from the network’s healthcare organizations.

Yet another Alzheimer’s drug has failed in late-stage clinical trials. vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in its Phase III STEADFAST clinical trial. It was being evaluated in patients with mild Alzheimer’s disease.

Shares of Ironwood Pharma have settled a bit after the company announced Monday that activist investor Alex Denner of Sarissa Capital was vying for a seat on the company board of directors.

There are a lot of factors that must come together in order to make a “great” workplace. A new report suggests that two of the key features of a great workplace are a “strong sense of purpose and lived-out values.”

Pfizer has signed a 20-year lease for its new company global headquarters. It will be, as reported earlier, at The Spiral, an office tower being built by Tishman Speyer at 66 Hudson Boulevard at Hudson Yards of Manhattan.

Most life science and biotech professionals are aware of the highly competitive process involved with trying to secure full-time positions in academia. Approximately 42% of life science professionals with doctorate degrees work in academia.* Unfortunately, only a fraction of them have full-time faculty positions.*

Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling. It will seek approval for a version of Illumina’s TruSight Tumor 170 as a companion diagnostic for Loxo Oncology’s larotrectinib and LOXO-292.

Swiss pharma giant Roche has had an active April so far. The company has acquired a multiple sclerosis program, completed the acquisition of a company and secured a big win with the United Kingdom’s healthcare provider for lung cancer drug Tecentriq.

Switzerland-based Novartis is buying Bannockburn, Illinois-based AveXis for $8.7 billion. This could spell big trouble for Cambridge, Massachusetts-based Biogen.